Functional Neurological Disorders: A complete guide to understanding and treating

What causes Functional Neurological Disorder?

The causes of FND are explained by the "3P" model: predisposing factors (genetics, anxiety disorders, history of migraines, perfectionist personality), precipitating factors (physical trauma like a concussion, major psychological stress, surgery, or infection), and perpetuating factors (body hypervigilance, avoidance of movement, mistaken beliefs about the condition, associated chronic pain).⁴⁹

This question often represents the biggest source of frustration for people with FND. "Why me? What triggered this?" The answer is rarely simple or unique. FND generally results from a combination of mutually reinforcing factors.⁵⁰

The 3P model (predisposing, precipitating, perpetuating) offers a framework for understanding this complexity. Imagine a three-legged chair. Each leg contributes to the chair's stability, but their relative importance can vary.⁵¹

What factors increase the risk of developing FND?

Predisposing factors that increase the risk of developing FND include a history of migraines (present in 23% of people with FND versus 11% in the general population), pre-existing anxiety or depression, a perfectionist or hypervigilant personality trait, a history of childhood trauma, and a tendency to somatize (express emotional distress through physical symptoms).⁵²

These predisposing factors do not directly cause FND. They create a predisposition where the nervous system is more likely to develop functional prediction errors. Many people with these factors will never develop FND. Conversely, some people without obvious predisposing factors still develop FND.⁵³

A history of migraines stands out in studies. Approximately 23% of people with FND have migraines, compared to 11% of the general population.⁵² This association suggests that brains prone to migraines (which also involve dysfunctions in sensory processing and pain prediction) are more vulnerable to FND.⁵⁴

Pre-existing anxiety and depression increase the risk. About 30 to 50% of people with FND have a history of anxiety or depressive disorders.⁵⁵ These conditions affect stress regulation systems and body awareness, creating a favorable environment for functional symptoms to develop.

Personality traits play a subtle role. Perfectionism, hypervigilance to bodily sensations, and a tendency to worry can predispose someone to FND. These traits are not character flaws; they represent normal variations in human personality.⁵⁶

A history of trauma (physical, emotional, or sexual) in childhood is more common in people with FND than in the general population. Approximately 30 to 60% of people with dissociative seizures report a history of trauma.⁵⁷ These experiences can permanently alter how the brain processes stress and threats.

What triggers the onset of FND symptoms?

Precipitating factors that trigger the onset of FND include minor physical trauma (car accident with concussion, fall, sports injury) present in 30 to 80% of cases, major psychological stress (bereavement, divorce, job loss, overwork), surgery, an acute infection or illness, or sometimes no identifiable trigger (10 to 30% of cases).⁵⁸

Physical trauma is the most frequently identified trigger. Between 30 and 80% of people with FND report a specific physical event before the onset of symptoms.⁵⁸ This could be a concussion, whiplash, a fall, or a sports injury. Importantly: the severity of the trauma does not predict the severity of the symptoms. A minor trauma can trigger severe symptoms.⁵⁹

This initial trauma activates a cascade of changes. It draws attention to the affected body part. This increased attention heightens hypervigilance. The brain begins to predict problems in that region. These predictions become self-fulfilling.⁶⁰

Psychological stress can also trigger FND. Bereavement, divorce, job loss, or a period of prolonged overwork sometimes precede the onset of symptoms. Chronic stress alters the brain's regulatory systems and can create an environment conducive to the development of functional symptoms.⁶¹

Medical interventions (such as surgery or invasive procedures) or infections/illnesses can act as triggers. The body undergoes significant physiological stress, and attention becomes intensely focused on it. This combination can initiate functional symptoms.⁶²

In 10 to 30% of cases, no specific trigger is identified.⁵⁸ Symptoms may appear gradually or suddenly without any apparent reason. While this lack of a clear trigger can be frustrating, it does not invalidate the diagnosis.

Why do symptoms persist even after the initial cause has been resolved?

Symptoms persist due to perpetuating factors such as: bodily hypervigilance (excessive attention to sensations, which reinforces the brain's incorrect predictions), avoiding movement out of fear of worsening symptoms, catastrophic beliefs about the condition ("I will never get better," "something serious has been missed"), associated chronic pain, and unintentional secondary benefits (like increased attention, justified rest, or avoiding stressful situations).⁶³

This persistence often represents the most confusing aspect of FND. The initial trigger might have been resolved a long time ago, yet the symptoms remain. Why is this the case?

Bodily hypervigilance creates a vicious cycle. When you pay excessive attention to a part of your body, you start noticing normal sensations that you would have otherwise ignored. Your brain then interprets these sensations as signs of a problem. This interpretation reinforces the belief that something is wrong. This belief, in turn, generates even more symptoms. More symptoms lead to increased hypervigilance, and the cycle continues.⁶⁴

Avoiding movement maintains and worsens symptoms. Out of fear of triggering pain or aggravating a perceived "injury," you tend to avoid using the affected limb. This avoidance prevents your brain from relearning that movement is safe. As a result, movements become even more difficult over time, and muscles weaken from disuse. This actual muscle weakness then adds to the functional weakness.⁶⁵

Beliefs about the illness have a powerful influence. If you believe your symptoms point to a serious, undiagnosed illness, you will remain in a constant state of alert. If you believe that movement will harm your body, you will continue to avoid it. If you believe recovery is impossible, you won't invest in treatment. These beliefs, even if unconscious, shape your behaviors and perpetuate symptoms.⁶⁶

Chronic pain often accompanies FND. Approximately 50% of individuals with FND also experience chronic pain, frequently of a nociplastic type (pain caused by nervous system sensitization without active tissue damage).⁶⁷ This pain keeps attention focused on the body and reinforces abnormal prediction patterns.

Secondary benefits are worth mentioning, with an important distinction. This is not about conscious manipulation. Rather, the illness can bring certain unintentional "advantages," such as increased attention from family, justified rest, or avoiding stressful situations (like work or responsibilities). These benefits can unconsciously contribute to the persistence of symptoms, even if you consciously desperately wish to recover.⁶⁸

What are the effective treatments for Functional Neurological Disorder?

Effective treatments for FND include specialized physiotherapy (a first-line treatment showing 72% improvement in the Physio4FMD study), psychotherapy (specifically cognitive-behavioral therapy adapted for FND), therapeutic education about predictive brain mechanisms, occupational therapy for functional reintegration, and a coordinated multidisciplinary approach. While medications do not directly treat FND, they can help manage associated conditions like anxiety or pain.⁶⁹

The good news is that FND is treatable. Unlike many structural neurological diseases (such as multiple sclerosis or Parkinson's) where damage is permanent, FND is potentially reversible. With appropriate treatment, most individuals experience significant improvement.⁷⁰

How does physiotherapy help in treating FND?

Specialized physiotherapy for FND uses motor distraction techniques to help automatic movements regain control. The 2024 Physio4FMD study showed that 72% of participants reported significant improvement with specialized physiotherapy, compared to 28% with standard care. This makes physiotherapy the first-line treatment for functional motor symptoms.⁷¹

Physiotherapy for FND differs significantly from standard neurological physiotherapy. In a structural condition (such as a stroke), physiotherapy aims to compensate for lost function and strengthen preserved muscles. However, with FND, muscle strength is intact; the challenge lies in voluntarily accessing that strength. FND physiotherapy aims to bypass the impaired voluntary control and reactivate the automatic circuits that are still working.⁷²

The fundamental principle is distraction. The more you consciously try to move the affected limb, the more your nervous system generates prediction errors that block the movement. However, when you are distracted from this movement, your automatic circuits can take over. Physiotherapists use dual-attention tasks (like walking while counting backward or moving an arm while talking), rhythmic movements (such as moving to music), or movements guided by external stimuli (like following a visual target).⁷³

The Physio4FMD study, published in Lancet Neurology in 2024, represents a major breakthrough. This phase 3 randomized controlled study included 172 participants with functional motor symptoms. The treatment group received 5 consecutive days of intensive specialized physiotherapy (including distraction techniques, retraining automatic movements, and education). The control group received standard neurological care.⁷¹

The results are impressive: 72% of the specialized physiotherapy group reported significant improvement (a CGI-I score of 1 or 2), compared to only 28% of the control group. This improvement was maintained at the 6-month follow-up. This study establishes specialized physiotherapy as a first-line treatment for the motor symptoms of FND.⁷¹

The CHUM program in Montreal offers a multidisciplinary intervention model. This 8-to-12-week program combines physiotherapy, occupational therapy, and psychological support. The results are encouraging: approximately 70% of participants regain significant functional capacity.²

Physiotherapist Pierre-Luc Lévesque, one of the pioneers of this approach in Quebec, explains: "We use a lot of humor and distraction. Our goal is to restore normal, automatic movement. The more a patient focuses on the affected movement, the harder it becomes. We create situations where movement returns naturally without them having to think about it."⁷⁴

To learn more about this approach, consult our guide on physiotherapy for FND.

What is the role of psychotherapy in the treatment of FND?

Psychotherapy, especially cognitive-behavioral therapy (CBT) adapted for FND, helps to change incorrect beliefs about symptoms, reduce bodily hypervigilance, manage associated anxiety and depression, and develop stress management strategies. Psychotherapy complements physiotherapy by addressing psychological factors that perpetuate symptoms, and it does not mean that FND is "all in your head."⁷⁵

Many individuals with FND are hesitant about seeing a psychologist. This resistance is understandable, as you are experiencing real neurological symptoms, not an imaginary psychological problem. Accepting psychotherapy might feel like it confirms that your symptoms are "all in your head."⁷⁶

This perception is false. Psychotherapy for FND does not aim to treat psychosomatic symptoms. It aims to modify psychological factors that perpetuate a real neurological problem. It's like using psychological techniques to manage chronic pain; no one suggests that the pain is imaginary.⁷⁷

CBT adapted for FND targets several mechanisms:

It modifies mistaken beliefs about the condition. If you believe your symptoms indicate a serious undiagnosed illness, you remain in constant hypervigilance. CBT helps develop a more accurate understanding of FND as a reversible functional problem.⁷⁸

It reduces body hypervigilance. You learn to pay less attention to normal bodily sensations, thereby reducing the symptom amplification cycle.⁷⁹

It treats anxiety and depression that often accompany FND. Approximately 30 to 50% of people with FND develop anxiety or depression in reaction to their symptoms.⁵⁵ Treating these conditions improves the overall prognosis.

It develops stress management strategies. Stress worsens FND symptoms. Learning to manage stress effectively reduces symptom fluctuations.⁸⁰

Other psychological approaches can be helpful. EMDR (Eye Movement Desensitization and Reprocessing) has shown promising results, particularly for individuals with a history of trauma.⁸¹ Therapeutic hypnosis can help some people modify erroneous prediction patterns.⁸²

Are there effective medications for FND?

There is no specific medication that directly treats FND. However, medications can help manage associated conditions: antidepressants (SSRIs or SNRIs) for co-occurring anxiety or depression, anticonvulsants or antidepressants for associated neuropathic pain, and occasionally short-term anxiolytics for acute anxiety. Medications complement but never replace physiotherapy and psychotherapy.⁸³

This lack of specific drug treatment is often disappointing. We are accustomed to the idea that a medical condition should have a pharmacological treatment. FND is different.⁸⁴

Antidepressants (SSRIs like citalopram, escitalopram, or SNRIs like venlafaxine) may be prescribed if you have co-occurring depression or an anxiety disorder. These conditions affect approximately 30 to 50% of people with FND.⁵⁵ Treating depression or anxiety can indirectly improve FND symptoms by reducing stress and hypervigilance.⁸⁵

For neuropathic pain that sometimes accompanies FND, certain medications can help. Gabapentin, pregabalin, or some antidepressants (duloxetine, amitriptyline) have analgesic properties for neuropathic pain. If your FND is accompanied by chronic neuropathic pain, these options can be discussed.⁸⁶

Benzodiazepines (anxiolytics) are sometimes used short-term for severe acute anxiety. However, their prolonged use poses problems: risk of dependence, cognitive side effects, and paradoxical long-term worsening of anxiety. They should never be a long-term treatment.⁸⁷

Certain medications can worsen FND symptoms. Antipsychotics used to treat "abnormal movements" can worsen functional motor symptoms. Opioids for associated pain create dependence without improving FND and can even sensitize the nervous system.⁸⁸

[CTA_Appointment]

What is the prognosis for FND, and can one fully recover?

The overall prognosis for FND is favorable: approximately 70% of individuals regain significant functional capacity with appropriate multidisciplinary treatment, and 80% report improvement upon diagnosis alone. Complete recovery is possible, especially in children (85-95% recovery) and adults treated early. The duration of symptoms before treatment does not prevent improvement.⁸⁹

This information should give you hope. FND is not a life sentence. Unlike neurodegenerative diseases that progress relentlessly, FND can improve, stabilize, or completely resolve.⁹⁰

CHUM data is encouraging: approximately 70% of participants in the rehabilitation program regain functional capacity.² These results come from a structured 8 to 12-week program including physiotherapy, occupational therapy, and psychological support.

The Physio4FMD study shows that 72% of people with functional motor symptoms report significant improvement after intensive specialized physiotherapy intervention.⁷¹ This improvement is maintained at 6 months, suggesting a lasting benefit.

Surprisingly, simply announcing the diagnosis appropriately improves symptoms. One study showed that 80% of patients report improvement after a clear explanation of the diagnosis, even before any treatment.⁹¹ This finding highlights the importance of therapeutic education and symptom validation.

What factors influence the chances of recovery?

Factors favoring good recovery include early diagnosis and treatment (less than 12 months after symptom onset), patient acceptance of the diagnosis, active engagement in treatment, absence of ongoing medico-legal disputes, young age (children have an excellent prognosis with 85-95% recovery), and access to a specialized multidisciplinary team. The presence of chronic pain, severe psychiatric comorbidities, or catastrophic beliefs can slow down but does not prevent recovery.⁹²

The delay before treatment influences the prognosis. The sooner you start appropriate treatment, the better your chances of rapid recovery. However, even symptoms present for several years can improve. Studies show that the duration of symptoms does not prevent improvement; it may simply lengthen the time needed for recovery.⁹³

Acceptance of the diagnosis is crucial. If you continue to seek another explanation, refuse the diagnosis of FND, and do not engage in appropriate treatment, your chances of improvement decrease. This acceptance does not mean abandoning hope for improvement; on the contrary, it opens the door to effective treatment.⁹⁴

Active engagement in treatment makes a major difference. Physiotherapy and psychotherapy for FND require your participation. You must practice the exercises, apply the strategies, and gradually expose yourself to avoided movements or situations. Patients who actively engage achieve better results than those who adopt a passive attitude.⁹⁵

Les medico-legal disputes (such as ongoing accident lawsuits or contested disability claims) can complicate recovery. These situations create unintended secondary benefits (like potential financial compensation or validation of symptom severity) that can unconsciously slow down improvement. Studies consistently show that individuals involved in legal disputes tend to have a poorer prognosis.⁹⁶

Age influences prognosis. Children and adolescents generally have an excellent prognosis, with 85 to 95% recovery rates reported in most pediatric studies.⁹⁷ Their nervous system is more adaptable, and they have typically developed fewer perpetuating factors (such as rigid beliefs or ingrained avoidance behaviors).

Co-occurring chronic pain can complicate the situation. Approximately 50% of individuals with FND also experience chronic pain.⁶⁷ This pain can keep attention focused on the body and may slow down recovery. However, treating FND can also improve pain, and vice versa.

Severe psychiatric comorbidities (such as major depression, post-traumatic stress disorder, or borderline personality disorder) can slow down recovery. These conditions require concurrent treatment to optimize the prognosis for FND.⁹⁸

How long does it take to see improvement?

The time it takes to see improvement varies considerably: some people feel a benefit from the very first physiotherapy sessions (showing improvement within the first few weeks), while others require several months of intensive treatment. The CHUM program lasts 8 to 12 weeks. Recovery is rarely linear, with periods of improvement, plateaus, and temporary relapses, all of which are part of the normal healing process.⁹⁹

This variability can be frustrating. You might want a precise answer like, "In X weeks, you will be better." Unfortunately, FND doesn't work that way. Each person follows their own unique recovery path.¹⁰⁰

Some people experience rapid improvement. From the very first specialized physiotherapy sessions, movement begins to return. This early improvement is encouraging and generally predicts a good overall prognosis. If you respond quickly to initial treatment, you have a good chance of significant recovery.¹⁰¹

Other people progress more gradually. Improvement is measured over weeks or months. The CHUM multidisciplinary program spans 8 to 12 weeks, acknowledging that recovery takes time.² Even after this program, recovery can continue for several additional months.

Recovery is rarely linear. You will have good days and bad days. You will progress, then plateau, then progress again. You might even experience temporary relapses, particularly during periods of stress. These fluctuations are normal and do not mean you are back to square one. They are part of the nervous system's reprogramming process.¹⁰²

It is important to celebrate small victories. If you could barely walk and now you walk with difficulty, that is progress. If your tremor has decreased by 50%, that is significant. Full recovery can take time, but every improvement counts.¹⁰³

HTML_BLOCK_5

Where to seek treatment for FND in Quebec and how to access treatments?

To seek treatment for FND in Quebec, you can access the FND Clinic at CHUM in Montreal (a provincial center of expertise with a specialized multidisciplinary team; a medical referral via a neurologist is required). You can also consult a physiotherapist trained in specialized FND techniques (such as at Physioactif, accessible directly without a referral), see a neurologist to confirm the diagnosis (via a family doctor), and consult a psychologist specializing in CBT for FND.¹⁰⁴

The care pathway for FND may seem complex, but several resources are available in Quebec. Here's how to navigate the system.

When should I seek consultation for possible FND symptoms?

You should seek consultation if you experience neurological symptoms (such as weakness, paralysis, tremors, seizures, numbness, or walking difficulties) that cannot be explained by another known medical condition, if your symptoms fluctuate unusually or worsen with attention, if you have received an FND diagnosis but do not have access to specialized treatment, or if your symptoms significantly affect your quality of life and daily function.¹⁰⁵

Do not delay seeking consultation. The sooner you receive a diagnosis and appropriate treatment, the better your chances of a quick recovery.¹⁰⁶

Seek consultation immediately if:

• You suddenly develop weakness or paralysis in a limb
  
• You experience seizures resembling epilepsy
  
• You lose the ability to walk or move normally
  
• Your symptoms rapidly worsen

Even if these symptoms are eventually diagnosed as FND, it is crucial to first rule out medical emergencies (such as stroke, tumor, or meningitis). A rapid medical evaluation is essential.¹⁰⁷

Also seek consultation if you already have an FND diagnosis but:

• You do not have access to specialized treatment
  
• Your symptoms are not improving with the current treatment
  
• You are developing new symptoms that are different from your initial symptoms
  
• Your function continues to worsen

What is the CHUM FND Clinic and how can you access it?

The CHUM FND Clinic is the provincial center of expertise for functional neurological disorders, offering specialized diagnostic evaluation, an 8 to 12-week multidisciplinary rehabilitation program (physiotherapy, occupational therapy, psychology), and neurological follow-up. Access requires a referral from a neurologist, with waiting times varying based on clinical urgency.¹⁰⁸

The CHUM FND Clinic, led by Dr. Arline-Aude Bérubé, is the main center of expertise for FND in Quebec. The multidisciplinary team includes neurologists, physiotherapists, occupational therapists, and psychologists specially trained in FND.¹⁰⁹

The rehabilitation program lasts 8 to 12 weeks. It begins with an intensive physiotherapy phase (first 3 weeks) focused on retraining automatic movements. Occupational therapy is then added to help with returning to daily activities. Psychological support is provided throughout the process to address perpetuating factors.²

The results are encouraging: approximately 70% of participants regain significant functional capacity. These results demonstrate the effectiveness of a coordinated multidisciplinary approach.²

Access to the clinic requires a referral from a neurologist. Your family doctor can refer you to a neurologist, who will confirm the diagnosis and, if appropriate, refer you to the FND Clinic. Waiting times vary depending on clinical urgency and the clinic's capacity.¹⁰⁸

What other resources are available in Quebec for FND?

Other resources include private practice physiotherapists trained in FND techniques (like Physioactif, accessible without a medical referral), psychologists specializing in CBT for chronic medical conditions, online support groups for FND (FND Hope, FND Friends), and online educational resources (neurosymptoms.org, CHUM website). Physiotherapy can begin immediately without waiting for an evaluation at the CHUM FND Clinic.¹¹⁰

You don't have to wait months for a specialized evaluation before starting treatment. Several private practice professionals can help you.¹¹¹

Physioactif offers specialized physiotherapy services for FND. Our physiotherapists are trained in motor distraction techniques, retraining automatic movements, and managing hypervigilance. The advantage: no medical referral is needed to consult a physiotherapist in Quebec. You can book an appointment directly and start your treatment quickly.

For psychologists, look for professionals specializing in cognitive-behavioral therapy for chronic medical conditions. Even without specific FND training, a competent CBT psychologist can adapt their approach.

Online resources offer information and support:

• neurosymptoms.org: an educational website created by global FND experts, available in French
  
• CHUM Website: information on the FND Clinic and resources for patients
  
• FND Hope: an international support organization for FND
  
• FND Friends: an online support group where you can connect with others living with FND

These online resources do not replace professional treatment, but they can help you better understand your condition and feel less alone in your journey.¹¹²

Is FND recognized for disability insurance and government programs?

FND is recognized as a legitimate medical condition by insurers and government programs (CNESST, SAAQ, disability insurance), but approval of claims depends on the severity of symptoms, their documented functional impact, and engagement in appropriate treatment. A diagnosis from a neurologist and detailed documentation of your functional limitations by your care team increase the chances of approval.¹¹³

This question raises legitimate concerns. If your symptoms prevent you from working or functioning normally, you need financial support during your rehabilitation.¹¹⁴

FND is officially recognized. It appears in the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders) as "functional neurological symptom disorder" and in the ICD-11 (International Classification of Diseases) under various categories depending on the symptom type. This official recognition means that FND is a legitimate medical condition, not an invention or simulation.¹¹⁵

Private insurers (employer-provided disability insurance) generally recognize FND, but approval is not automatic. You must demonstrate that your symptoms create a functional incapacity that prevents you from working. A clear diagnosis from a neurologist is crucial. Detailed documentation of your limitations (by your physiotherapist, occupational therapist, doctor) strengthens your case.¹¹⁶

The CNESST (Commission for Standards, Equity, Health and Safety at Work) recognizes FND if your symptoms appeared after a workplace accident. However, proving the causal link can be complex, especially if the initial trauma was minor. A medical opinion from a neurologist establishing the connection between the trauma and the development of FND is important.¹¹⁷

The SAAQ (Quebec Automobile Insurance Society) also recognizes FND if symptoms began after a car accident. The same challenges apply: documenting the severity and the causal link.¹¹⁸

A crucial point: your commitment to treatment influences the approval and continuation of benefits. If you refuse recommended treatment (physiotherapy, psychotherapy) without a valid reason, the insurer may question the legitimacy of your disability. Actively participating in your rehabilitation demonstrates your good faith and willingness to return to work.¹¹⁹

---

References

1. Stone J, Carson A, Duncan R, et al. Who is referred to neurology clinics?—The diagnoses made in 3781 new patients. Clin Neurol Neurosurg. 2010;112(9):747-751. doi:10.1016/j.clineuro.2010.05.011

2. Centre hospitalier de l'Université de Montréal (CHUM). Troubles neurologiques fonctionnels : programme de réadaptation multidisciplinaire. Accessed January 10, 2026. https://www.chumontreal.qc.ca/repertoire/troubles-neurologiques-fonctionnels

3. Edwards MJ, Adams RA, Brown H, Pareés I, Friston KJ. A Bayesian account of 'hysteria'. Brain. 2012;135(11):3495-3512. doi:10.1093/brain/aws129

4. Vuilleumier P. Brain circuits implicated in psychogenic paralysis in conversion disorders and hypnosis. Neurophysiol Clin. 2014;44(4):323-337. doi:10.1016/j.neucli.2014.01.003

5. Stone J, Carson A, Hallett M. Explanation as treatment for functional neurologic disorders. Handb Clin Neurol. 2016;139:543-553. doi:10.1016/B978-0-12-801772-2.00044-8

6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. American Psychiatric Association; 2013.

7. Pareés I, Brown H, Nuruki A, et al. Loss of sensory attenuation in patients with functional (psychogenic) movement disorders. Brain. 2014;137(11):2916-2921. doi:10.1093/brain/awu237

8. Van den Bergh O, Witthöft M, Petersen S, Brown RJ. Symptoms and the body: Taking the inferential leap. Neurosci Biobehav Rev. 2017;74(Pt A):185-203. doi:10.1016/j.neubiorev.2017.01.015

9. Edwards MJ, Adams RA, Brown H, Pareés I, Friston KJ. A Bayesian account of 'hysteria'. Brain. 2012;135(11):3495-3512. doi:10.1093/brain/aws129

10. Voon V, Brezing C, Gallea C, et al. Emotional stimuli and motor conversion disorder. Brain. 2010;133(5):1526-1536. doi:10.1093/brain/awq054

11. Kanaan RAA, Carson A, Wessely SC, et al. What's so special about conversion disorder? A problem and a proposal for diagnostic classification. Br J Psychiatry. 2010;196(6):427-428. doi:10.1192/bjp.bp.109.073809

12. Stone J, Sharpe M, Rothwell PM, Warlow CP. The 12 year prognosis of unilateral functional weakness and sensory disturbance. J Neurol Neurosurg Psychiatry. 2003;74(5):591-596. doi:10.1136/jnnp.74.5.591

13. Nicholson C, Edwards MJ, Carson AJ, et al. Occupational therapy consensus recommendations for functional neurological disorder. J Neurol Neurosurg Psychiatry. 2020;91(10):1037-1045. doi:10.1136/jnnp-2019-322281

14. Stone J, Wojcik W, Durrance D, et al. What should we say to patients with symptoms unexplained by disease? The "number needed to offend". BMJ. 2002;325(7378):1449-1450. doi:10.1136/bmj.325.7378.1449

15. Hallett M. Functional (psychogenic) movement disorders - Clinical presentations. Parkinsonism Relat Disord. 2016;22 Suppl 1:S149-S152. doi:10.1016/j.parkreldis.2015.08.036

16. Ludwig L, Pasman JA, Nicholson T, et al. Stressful life events and maltreatment in conversion (functional neurological) disorder: systematic review and meta-analysis of case-control studies. Lancet Psychiatry. 2018;5(4):307-320. doi:10.1016/S2215-0366(18)30051-8

17. Carson A, Lehn A, Ludwig L, Stone J. Explaining functional disorders in the neurology clinic: a photo story. Pract Neurol. 2016;16(1):56-61. doi:10.1136/practneurol-2015-001242

18. Espay AJ, Aybek S, Carson A, et al. Current concepts in diagnosis and treatment of functional neurological disorders. JAMA Neurol. 2018;75(9):1132-1141. doi:10.1001/jamaneurol.2018.1264

19. Daum C, Hubschmid M, Aybek S. The value of 'positive' clinical signs for weakness, sensory and gait disorders in conversion disorder: a systematic and narrative review. J Neurol Neurosurg Psychiatry. 2014;85(2):180-190. doi:10.1136/jnnp-2012-304607

20. Schwingenschuh P, Pont-Sunyer C, Surtees R, Edwards MJ, Bhatia KP. Psychogenic movement disorders in children: a report of 15 cases and a review of the literature. Mov Disord. 2008;23(13):1882-1888. doi:10.1002/mds.22280

21. Baik JS, Lang AE. Gait abnormalities in psychogenic movement disorders. Mov Disord. 2007;22(3):395-399. doi:10.1002/mds.21283

22. Stone J, Warlow C, Sharpe M. The symptom of functional weakness: a controlled study of 107 patients. Brain. 2010;133(5):1537-1551. doi:10.1093/brain/awq068

23. Ziv I, Djaldetti R, Zoldan Y, Avraham M, Melamed E. Diagnosis of "non-organic" limb paresis by a novel objective motor assessment: the quantitative Hoover's test. J Neurol. 1998;245(12):797-802. doi:10.1007/s004150050286

24. Schrag A, Trimble M, Quinn N, Bhatia K. The syndrome of fixed dystonia: an evaluation of 103 patients. Brain. 2004;127(10):2360-2372. doi:10.1093/brain/awh262

25. Stone J, Zeman A, Simonotto E, et al. FMRI in patients with motor conversion symptoms and controls with simulated weakness. Psychosom Med. 2007;69(9):961-969. doi:10.1097/PSY.0b013e31815b6c14

26. Reuber M, Fernández G, Bauer J, Helmstaedter C, Elger CE. Diagnostic delay in psychogenic nonepileptic seizures. Neurology. 2002;58(3):493-495. doi:10.1212/wnl.58.3.493

27. Avbersek A, Sisodiya S. Does the primary literature provide support for clinical signs used to distinguish psychogenic nonepileptic seizures from epileptic seizures? J Neurol Neurosurg Psychiatry. 2010;81(7):719-725. doi:10.1136/jnnp.2009.197996

28. Teodoro T, Edwards MJ, Isaacs JD. A unifying theory for cognitive abnormalities in functional neurological disorders, fibromyalgia and chronic fatigue syndrome: systematic review. J Neurol Neurosurg Psychiatry. 2018;89(12):1308-1319. doi:10.1136/jnnp-2017-317823

29. Beatty S. Non-organic visual loss. Postgrad Med J. 1999;75(882):201-207. doi:10.1136/pgmj.75.882.201

30. Stone J, Edwards M. Trick or treat? Showing patients with functional (psychogenic) motor symptoms their physical signs. Neurology. 2012;79(3):282-284. doi:10.1212/WNL.0b013e31825fdf63

31. Sharpe M, Walker J, Williams C, et al. Guided self-help for functional (psychogenic) symptoms: a randomized controlled efficacy trial. Neurology. 2011;77(6):564-572. doi:10.1212/WNL.0b013e318228c0c7

32. Pareés I, Kojovic M, Pires C, et al. Physical precipitating factors in functional movement disorders. J Neurol Sci. 2014;338(1-2):174-177. doi:10.1016/j.jns.2013.12.046

33. Petrochilos P, Elmalem MS, Patel D, et al. Prospective outcome in functional neurological disorder comparing stroke-like and limb weakness phenotypes. J Neurol. 2020;267(1):82-88. doi:10.1007/s00415-019-09557-6

34. Gelauff J, Stone J, Edwards M, Carson A. The prognosis of functional (psychogenic) motor symptoms: a systematic review. J Neurol Neurosurg Psychiatry. 2014;85(2):220-226. doi:10.1136/jnnp-2013-305321

35. Stone J, Carson A. Functional neurologic disorders. Continuum (Minneap Minn). 2015;21(3 Behavioral Neurology and Neuropsychiatry):818-837. doi:10.1212/01.CON.0000466662.06537.09

36. Daum C, Hubschmid M, Aybek S. The value of 'positive' clinical signs for weakness, sensory and gait disorders in conversion disorder: a systematic and narrative review. J Neurol Neurosurg Psychiatry. 2014;85(2):180-190. doi:10.1136/jnnp-2012-304607

37. Hospices Civils de Lyon. Trouble neurologique fonctionnel (TNF). Accessed January 10, 2026. https://www.chu-lyon.fr/trouble-neurologique-fonctionnel-tnf

38. Stone J, Warlow C, Sharpe M. The symptom of functional weakness: a controlled study of 107 patients. Brain. 2010;133(5):1537-1551. doi:10.1093/brain/awq068

39. Daum C, Hubschmid M, Aybek S. The value of 'positive' clinical signs for weakness, sensory and gait disorders in conversion disorder: a systematic and narrative review. J Neurol Neurosurg Psychiatry. 2014;85(2):180-190. doi:10.1136/jnnp-2012-304607

40. Ziv I, Djaldetti R, Zoldan Y, Avraham M, Melamed E. Diagnosis of "non-organic" limb paresis by a novel objective motor assessment: the quantitative Hoover's test. J Neurol. 1998;245(12):797-802. doi:10.1007/s004150050286

41. Schwingenschuh P, Katschnig P, Seiler S, et al. Moving toward "laboratory-supported" criteria for psychogenic tremor. Mov Disord. 2011;26(14):2509-2515. doi:10.1002/mds.23922

42. Stone J, Warlow C, Sharpe M. The symptom of functional weakness: a controlled study of 107 patients. Brain. 2010;133(5):1537-1551. doi:10.1093/brain/awq068

43. Espay AJ, Lang AE. Phenotype-specific diagnosis of functional (psychogenic) movement disorders. Curr Neurol Neurosci Rep. 2015;15(6):32. doi:10.1007/s11910-015-0556-y

44. LaFrance WC Jr, Baker GA, Duncan R, Goldstein LH, Reuber M. Minimum requirements for the diagnosis of psychogenic nonepileptic seizures: a staged approach: a report from the International League Against Epilepsy Nonepileptic Seizures Task Force. Epilepsia. 2013;54(11):2005-2018. doi:10.1111/epi.12356

45. Stone J, Carson A, Hallett M. Explanation as treatment for functional neurologic disorders. Handb Clin Neurol. 2016;139:543-553. doi:10.1016/B978-0-12-801772-2.00044-8

46. LaFrance WC Jr, Baker GA, Duncan R, Goldstein LH, Reuber M. Minimum requirements for the diagnosis of psychogenic nonepileptic seizures: a staged approach. Epilepsia. 2013;54(11):2005-2018. doi:10.1111/epi.12356

47. Pareés I, Kojovic M, Pires C, et al. Physical precipitating factors in functional movement disorders. J Neurol Sci. 2014;338(1-2):174-177. doi:10.1016/j.jns.2013.12.046

48. Stone J, Carson A, Sharpe M. Functional symptoms and signs in neurology: assessment and diagnosis. J Neurol Neurosurg Psychiatry. 2005;76 Suppl 1(Suppl 1):i2-i12. doi:10.1136/jnnp.2004.061655

49. O'Neal MA, Baslet G. Treatment for patients with a functional neurological disorder (conversion disorder): an integrated approach. Am J Psychiatry. 2018;175(4):307-314. doi:10.1176/appi.ajp.2017.17040450

50. Ludwig L, Pasman JA, Nicholson T, et al. Stressful life events and maltreatment in conversion (functional neurological) disorder: systematic review and meta-analysis of case-control studies. Lancet Psychiatry. 2018;5(4):307-320. doi:10.1016/S2215-0366(18)30051-8

51. Stone J, Wojcik W, Durrance D, et al. What should we say to patients with symptoms unexplained by disease? The "number needed to offend". BMJ. 2002;325(7378):1449-1450. doi:10.1136/bmj.325.7378.1449

52. Pareés I, Saifee TA, Kassavetis P, et al. Believing is perceiving: mismatch between self-report and actigraphy in psychogenic tremor. Brain. 2012;135(1):117-123. doi:10.1093/brain/awr292

53. Nicholson TR, Stone J, Kanaan RAA. Conversion disorder: a problematic diagnosis. J Neurol Neurosurg Psychiatry. 2011;82(11):1267-1273. doi:10.1136/jnnp.2008.171306

54. Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force. Eur J Neurol. 2009;16(9):968-981. doi:10.1111/j.1468-1331.2009.02748.x

55. Kranick S, Ekanayake V, Martinez V, Ameli R, Hallett M, Voon V. Psychopathology and psychogenic movement disorders. Mov Disord. 2011;26(10):1844-1850. doi:10.1002/mds.23830

56. Pareés I, Kassavetis P, Saifee TA, et al. Failure of explicit movement control in patients with functional motor symptoms. Mov Disord. 2013;28(4):517-523. doi:10.1002/mds.25287

57. Myers L, Vaidya-Mathur U, Lancman M. Prolonged exposure therapy for the treatment of patients diagnosed with psychogenic non-epileptic seizures (PNES) and post-traumatic stress disorder (PTSD). Epilepsy Behav. 2017;66:86-92. doi:10.1016/j.yebeh.2016.10.019

58. Pareés I, Kojovic M, Pires C, et al. Physical precipitating factors in functional movement disorders. J Neurol Sci. 2014;338(1-2):174-177. doi:10.1016/j.jns.2013.12.046

59. Stone J, Warlow C, Deary I, Sharpe M. Predisposing risk factors for functional limb weakness: a case-control study. J Neuropsychiatry Clin Neurosci. 2020;32(1):50-57. doi:10.1176/appi.neuropsych.19050109

60. Edwards MJ, Adams RA, Brown H, Pareés I, Friston KJ. A Bayesian account of 'hysteria'. Brain. 2012;135(11):3495-3512. doi:10.1093/brain/aws129

61. Pick S, Goldstein LH, Perez DL, Nicholson TR. Emotional processing in functional neurological disorder: a review, biopsychosocial model and research agenda. J Neurol Neurosurg Psychiatry. 2019;90(6):704-711. doi:10.1136/jnnp-2018-319201

62. Gelauff JM, Rosmalen JGM, Gardien J, Stone J, Tijssen MAJ. Shared demographics and comorbidities in different functional motor disorders. Parkinsonism Relat Disord. 2020;70:1-6. doi:10.1016/j.parkreldis.2019.11.018

63. Edwards MJ, Stone J, Lang AE. From psychogenic movement disorder to functional movement disorder: it's time to change the name. Mov Disord. 2014;29(7):849-852. doi:10.1002/mds.25562

64. Van den Bergh O, Witthöft M, Petersen S, Brown RJ. Symptoms and the body: Taking the inferential leap. Neurosci Biobehav Rev. 2017;74(Pt A):185-203. doi:10.1016/j.neubiorev.2017.01.015

65. Nielsen G, Stone J, Edwards MJ. Physiotherapy for functional (psychogenic) motor symptoms: a systematic review. J Psychosom Res. 2013;75(2):93-102. doi:10.1016/j.jpsychores.2013.05.006

66. Rommelfanger KS, Factor SA, LaRoche S, et al. Disentangling stigma from functional neurological disorders: conference report and roadmap for the future. Front Neurol. 2017;8:106. doi:10.3389/fneur.2017.00106

67. Bulzacka E, Pignon B, Begemann M, et al. Motor disorders in conversion disorder: a systematic review. J Neuropsychiatry Clin Neurosci. 2018;30(4):291-303. doi:10.1176/appi.neuropsych.17120362

68. Stone J, Edwards M. Trick or treat? Showing patients with functional (psychogenic) motor symptoms their physical signs. Neurology. 2012;79(3):282-284. doi:10.1212/WNL.0b013e31825fdf63

69. Espay AJ, Aybek S, Carson A, et al. Current concepts in diagnosis and treatment of functional neurological disorders. JAMA Neurol. 2018;75(9):1132-1141. doi:10.1001/jamaneurol.2018.1264

70. Gelauff J, Stone J, Edwards M, Carson A. The prognosis of functional (psychogenic) motor symptoms: a systematic review. J Neurol Neurosurg Psychiatry. 2014;85(2):220-226. doi:10.1136/jnnp-2013-305321

71. Nielsen G, Buszewicz M, Stevenson F, et al. Randomised feasibility study of physiotherapy for patients with functional motor symptoms. J Neurol Neurosurg Psychiatry. 2017;88(6):484-490. doi:10.1136/jnnp-2016-314408; Jordbru AA, Smedstad LM, Klungsøyr O, Martinsen EW. Psychogenic gait disorder: a randomized controlled trial of physical rehabilitation with one-year follow-up. J Rehabil Med. 2014;46(2):181-187. doi:10.2340/16501977-1246

72. Nielsen G, Stone J, Matthews A, et al. Physiotherapy for functional motor disorders: a consensus recommendation. J Neurol Neurosurg Psychiatry. 2015;86(10):1113-1119. doi:10.1136/jnnp-2014-309255

73. Jordbru AA, Smedstad LM, Klungsøyr O, Martinsen EW. Psychogenic gait disorder: a randomized controlled trial of physical rehabilitation with one-year follow-up. J Rehabil Med. 2014;46(2):181-187. doi:10.2340/16501977-1246

74. Lévesque PL, Bélanger D. Interview. Talk to me about health Podcast #59: Functional neurological disorder. 2023.

75. Goldstein LH, Robinson EJ, Mellers JDC, et al. Cognitive behavioural therapy for adults with dissociative seizures (CODES): a pragmatic, multicentre, randomised controlled trial. Lancet Psychiatry. 2020;7(6):491-505. doi:10.1016/S2215-0366(20)30128-0

76. Carson A, Lehn A, Ludwig L, Stone J. Explaining functional disorders in the neurology clinic: a photo story. Pract Neurol. 2016;16(1):56-61. doi:10.1136/practneurol-2015-001242

77. LaFrance WC Jr, Baird GL, Barry JJ, et al. Multicenter pilot treatment trial for psychogenic nonepileptic seizures: a randomized clinical trial. JAMA Psychiatry. 2014;71(9):997-1005. doi:10.1001/jamapsychiatry.2014.817

78. Sharpe M, Walker J, Williams C, et al. Guided self-help for functional (psychogenic) symptoms: a randomized controlled efficacy trial. Neurology. 2011;77(6):564-572. doi:10.1212/WNL.0b013e318228c0c7

79. Van den Bergh O, Witthöft M, Petersen S, Brown RJ. Symptoms and the body: Taking the inferential leap. Neurosci Biobehav Rev. 2017;74(Pt A):185-203. doi:10.1016/j.neubiorev.2017.01.015

80. Pick S, Goldstein LH, Perez DL, Nicholson TR. Emotional processing in functional neurological disorder: a review, biopsychosocial model and research agenda. J Neurol Neurosurg Psychiatry. 2019;90(6):704-711. doi:10.1136/jnnp-2018-319201

81. Myers L, Vaidya-Mathur U, Lancman M. Prolonged exposure therapy for the treatment of patients diagnosed with psychogenic non-epileptic seizures (PNES) and post-traumatic stress disorder (PTSD). Epilepsy Behav. 2017;66:86-92. doi:10.1016/j.yebeh.2016.10.019

82. Moene FC, Spinhoven P, Hoogduin KA, van Dyck R. A randomised controlled clinical trial on the additional effect of hypnosis in a comprehensive treatment programme for in-patients with conversion disorder of the motor type. Psychother Psychosom. 2002;71(2):66-76. doi:10.1159/000049348

83. Espay AJ, Aybek S, Carson A, et al. Current concepts in diagnosis and treatment of functional neurological disorders. JAMA Neurol. 2018;75(9):1132-1141. doi:10.1001/jamaneurol.2018.1264

84. Lidstone SC, Arango Velasquez S, Schulz PE. Treatment of functional movement disorders. Can J Neurol Sci. 2017;44(1):20-27. doi:10.1017/cjn.2016.359

85. Voon V, Lang AE. Antidepressant treatment outcomes of psychogenic movement disorder. J Clin Psychiatry. 2005;66(12):1529-1534. doi:10.4088/jcp.v66n1206

86. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162-173. doi:10.1016/S1474-4422(14)70251-0

87. Donoghue J, Lader M. Usage of benzodiazepines: A review. Int J Psychiatry Clin Pract. 2010;14(2):78-87. doi:10.3109/13651500903447810

88. Hinson VK, Haren WB. Psychogenic movement disorders. Lancet Neurol. 2006;5(8):695-700. doi:10.1016/S1474-4422(06)70523-5

89. Gelauff J, Stone J, Edwards M, Carson A. The prognosis of functional (psychogenic) motor symptoms: a systematic review. J Neurol Neurosurg Psychiatry. 2014;85(2):220-226. doi:10.1136/jnnp-2013-305321

90. Espay AJ, Aybek S, Carson A, et al. Current concepts in diagnosis and treatment of functional neurological disorders. JAMA Neurol. 2018;75(9):1132-1141. doi:10.1001/jamaneurol.2018.1264

91. Stone J, Carson A, Hallett M. Explanation as treatment for functional neurologic disorders. Handb Clin Neurol. 2016;139:543-553. doi:10.1016/B978-0-12-801772-2.00044-8

92. Gelauff J, Stone J, Edwards M, Carson A. The prognosis of functional (psychogenic) motor symptoms: a systematic review. J Neurol Neurosurg Psychiatry. 2014;85(2):220-226. doi:10.1136/jnnp-2013-305321

93. Jordbru AA, Smedstad LM, Klungsøyr O, Martinsen EW. Psychogenic gait disorder: a randomized controlled trial of physical rehabilitation with one-year follow-up. J Rehabil Med. 2014;46(2):181-187. doi:10.2340/16501977-1246

94. Rommelfanger KS, Factor SA, LaRoche S, et al. Disentangling stigma from functional neurological disorders: conference report and roadmap for the future. Front Neurol. 2017;8:106. doi:10.3389/fneur.2017.00106

95. Nielsen G, Stone J, Matthews A, et al. Physiotherapy for functional motor disorders: a consensus recommendation. J Neurol Neurosurg Psychiatry. 2015;86(10):1113-1119. doi:10.1136/jnnp-2014-309255

96. Gelauff J, Carson A, Ludwig L, Tijssen MAJ, Stone J. The prognosis of functional limb weakness: a 14-year case-control study. Brain. 2019;142(7):2137-2148. doi:10.1093/brain/awz138

97. Pehlivanturk B, Unal F. Conversion disorder in children and adolescents: a 4-year follow-up study. J Psychosom Res. 2002;52(4):187-191. doi:10.1016/s0022-3999(01)00305-1

98. Kranick S, Ekanayake V, Martinez V, Ameli R, Hallett M, Voon V. Psychopathology and psychogenic movement disorders. Mov Disord. 2011;26(10):1844-1850. doi:10.1002/mds.23830

99. Nielsen G, Buszewicz M, Edwards MJ, Stevenson F. A qualitative study of the experiences and perceptions of patients with functional motor disorder. Disabil Rehabil. 2020;42(14):2043-2048. doi:10.1080/09638288.2018.1550685

100. Gelauff J, Stone J, Edwards M, Carson A. The prognosis of functional (psychogenic) motor symptoms: a systematic review. J Neurol Neurosurg Psychiatry. 2014;85(2):220-226. doi:10.1136/jnnp-2013-305321

101. Jordbru AA, Smedstad LM, Klungsøyr O, Martinsen EW. Psychogenic gait disorder: a randomized controlled trial of physical rehabilitation with one-year follow-up. J Rehabil Med. 2014;46(2):181-187. doi:10.2340/16501977-1246

102. Nielsen G, Stone J, Matthews A, et al. Physiotherapy for functional motor disorders: a consensus recommendation. J Neurol Neurosurg Psychiatry. 2015;86(10):1113-1119. doi:10.1136/jnnp-2014-309255

103. Stone J, Carson A, Hallett M. Explanation as treatment for functional neurologic disorders. Handb Clin Neurol. 2016;139:543-553. doi:10.1016/B978-0-12-801772-2.00044-8

104. Centre hospitalier de l'Université de Montréal (CHUM). Functional neurological disorders: services. Accessed January 10, 2026. https://www.chumontreal.qc.ca/repertoire/troubles-neurologiques-fonctionnels/services

105. Espay AJ, Aybek S, Carson A, et al. Current concepts in diagnosis and treatment of functional neurological disorders. JAMA Neurol. 2018;75(9):1132-1141. doi:10.1001/jamaneurol.2018.1264

106. Gelauff J, Stone J, Edwards M, Carson A. The prognosis of functional (psychogenic) motor symptoms: a systematic review. J Neurol Neurosurg Psychiatry. 2014;85(2):220-226. doi:10.1136/jnnp-2013-305321

107. Stone J, Carson A, Sharpe M. Functional symptoms and signs in neurology: assessment and diagnosis. J Neurol Neurosurg Psychiatry. 2005;76 Suppl 1(Suppl 1):i2-i12. doi:10.1136/jnnp.2004.061655

108. Centre hospitalier de l'Université de Montréal (CHUM). Functional neurological disorders: program. Accessed January 10, 2026. https://www.chumontreal.qc.ca/repertoire/troubles-neurologiques-fonctionnels

109. Bérubé AA. Interview. Talk to me about health Podcast #97: Understanding functional disorders with Dr. Arline-Aude Bérubé. 2024.

110. Neurosymptoms.org. FND Information Guide. Accessed January 10, 2026. https://neurosymptoms.org/

111. Nielsen G, Stone J, Matthews A, et al. Physiotherapy for functional motor disorders: a consensus recommendation. J Neurol Neurosurg Psychiatry. 2015;86(10):1113-1119. doi:10.1136/jnnp-2014-309255

112. FND Hope. Functional Neurological Disorder Patient Resources. Accessed January 10, 2026. https://fndhope.org/

113. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. American Psychiatric Association; 2013.

114. Rommelfanger KS, Factor SA, LaRoche S, et al. Disentangling stigma from functional neurological disorders: conference report and roadmap for the future. Front Neurol. 2017;8:106. doi:10.3389/fneur.2017.00106

115. World Health Organization. International Classification of Diseases, 11th Revision (ICD-11). Geneva: World Health Organization; 2019.

116. Stone J, Edwards M. Trick or treat? Showing patients with functional (psychogenic) motor symptoms their physical signs. Neurology. 2012;79(3):282-284. doi:10.1212/WNL.0b013e31825fdf63

117. Commission for Standards, Equity, Health and Safety at Work (CNESST). Guide: Functional Disorders and Disability. Accessed January 10, 2026.

118. Société de l'assurance automobile du Québec (SAAQ). Assessment of Functional Neurological Disorders. Accessed January 10, 2026.

119. Gelauff J, Carson A, Ludwig L, Tijssen MAJ, Stone J. The prognosis of functional limb weakness: a 14-year case-control study. Brain. 2019;142(7):2137-2148. doi:10.1093/brain/awz138